Mehmet Yasar
Research Subjects
Mehmet Yasar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abdülkerim Tamer
Aydın Adnan Menderes University, Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Aydın, Türkiye
1 shared publication - Busra Soysal
Department of Internal Medicine Adana City Training and Research Hospital Adana Turkey
1 shared publication - Dilek Gogas Yavuz
Department of Endocrinology and Metabolism, Marmara University Faculty of Medicine, Istanbul, Turkey
1 shared publication - Engin Onan
Department of Nephrology, Dr. Turgut Noyan Training and Research Hospital, Baskent University, 01250 Adana, Turkey
1 shared publication - Feyyaz Baltacioglu
Department of Radiology, Marmara University School of Medicine, Istanbul, Turkey
1 shared publication - Filiz Alkan Baylan
Department of Biochemistry, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Association Between Dialysis Dose and Atherogenic Index of Plasma in Maintenance Hemodialysis Patients: The Role of Body Weight
This study aimed to evaluate the association between single-pool Kt/V (spKt/V) and the atherogenic index of plasma (AIP) in maintenance hemodialysis patients and to investigate the potential influence of body weight on this relationship. Sixty adult patients receiving maintenance hemodialysis were included in this single-center, cross-sectional study. AIP was calculated as log10[triglyceride/HDL cholesterol], using concentrations expressed in mmol/L. Associations between spKt/V and lipid parameters were assessed using Pearson and Spearman correlation analyses, and multivariable linear regression models were constructed with AIP as the dependent variable. The mean age was 59.6±14.8 years, 60.0% of patients were male, and 30.0% had diabetes mellitus. Mean spKt/V and AIP were 1.60±0.16 and 0.172±0.238, respectively. spKt/V was inversely correlated with AIP (Pearson r=-0.350, p=0.006; Spearman ρ=-0.285, p=0.027) and positively correlated with HDL cholesterol. No significant associations were observed with LDL cholesterol or total cholesterol. In unadjusted linear regression, higher spKt/V was associated with lower AIP (B=-0.507, p=0.006). The association was attenuated after adjustment for age, sex, and diabetes (B=-0.348, p=0.050) and became nonsignificant after further adjustment for body weight and hemodialysis vintage (B=-0.228, p=0.240). Higher spKt/V was associated with a more favorable triglyceride–HDL profile; however, this association was attenuated after adjustment for body weight and hemodialysis vintage, and an independent association with AIP was not demonstrated in the fully adjusted model. These findings suggest that body size may substantially influence the observed relationship between spKt/V and the atherogenic lipid phenotype.
- 22 October 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Open AccessAssociation Between Dialysis Dose and Atherogenic Index of Plasma in Maintenance Hemodialysis Patients: The Role of Body Weight
This study aimed to evaluate the association between single-pool Kt/V (spKt/V) and the atherogenic index of plasma (AIP) in maintenance hemodialysis patients and to investigate the potential influence of body weight on this relationship. Sixty adult patients receiving maintenance hemodialysis were included in this single-center, cross-sectional study. AIP was calculated as log10[triglyceride/HDL cholesterol], using concentrations expressed in mmol/L. Associations between spKt/V and lipid parameters were assessed using Pearson and Spearman correlation analyses, and multivariable linear regression models were constructed with AIP as the dependent variable. The mean age was 59.6±14.8 years, 60.0% of patients were male, and 30.0% had diabetes mellitus. Mean spKt/V and AIP were 1.60±0.16 and 0.172±0.238, respectively. spKt/V was inversely correlated with AIP (Pearson r=-0.350, p=0.006; Spearman ρ=-0.285, p=0.027) and positively correlated with HDL cholesterol. No significant associations were observed with LDL cholesterol or total cholesterol. In unadjusted linear regression, higher spKt/V was associated with lower AIP (B=-0.507, p=0.006). The association was attenuated after adjustment for age, sex, and diabetes (B=-0.348, p=0.050) and became nonsignificant after further adjustment for body weight and hemodialysis vintage (B=-0.228, p=0.240). Higher spKt/V was associated with a more favorable triglyceride–HDL profile; however, this association was attenuated after adjustment for body weight and hemodialysis vintage, and an independent association with AIP was not demonstrated in the fully adjusted model. These findings suggest that body size may substantially influence the observed relationship between spKt/V and the atherogenic lipid phenotype.
- Open Access
- 4 May 2026
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 51 (4) , 690-696
Relationship between asprosin and insulin resistance in hypothyroidism
Objectives: Thyroid dysfunction is a common disorder associated with changes in body metabolism and low-grade inflammation. Associated with insulin resistance (IR), asprosin is a newly discovered peptide hormone. Asprosin promotes hepatic glucose production. This study was designed to evaluate the relationship between asprosin and IR in patients with overt and subclinical hypothyroidism and to compare the findings with a euthyroid healthy control group. Methods: The study included 30 patients diagnosed with hypothyroidism, 29 patients diagnosed with subclinical hypothyroidism, and 30 healthy individuals. Serum asprosin concentrations, glucose concentrations, and HOMA-IR indices of the groups were compared. Results: The mean age was 37.8 years, and 77.5 % (69/89) of participants were female. We found that circulating asprosin concentrations were elevated in patients with overt and subclinical hypothyroidism compared to controls. Asprosin concentrations were positively correlated with TSH, Anti TPO, Anti TG, glucose, insulin, HOMA-IR and negatively correlated with FT4 and FT3. Conclusions: For the first time in the literature, this study has shown that asprosin concentration is increased in patients with hypothyroidism, and that increased asprosin concentrations are associated with increased serum glucose concentration and HOMA-IR index. Therefore, asprosin may be a useful new marker for early metabolic disorders in hypothyroid patients.
- 4 May 2026
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 51 (4) , 690-696
Open AccessRelationship between asprosin and insulin resistance in hypothyroidism
Objectives: Thyroid dysfunction is a common disorder associated with changes in body metabolism and low-grade inflammation. Associated with insulin resistance (IR), asprosin is a newly discovered peptide hormone. Asprosin promotes hepatic glucose production. This study was designed to evaluate the relationship between asprosin and IR in patients with overt and subclinical hypothyroidism and to compare the findings with a euthyroid healthy control group. Methods: The study included 30 patients diagnosed with hypothyroidism, 29 patients diagnosed with subclinical hypothyroidism, and 30 healthy individuals. Serum asprosin concentrations, glucose concentrations, and HOMA-IR indices of the groups were compared. Results: The mean age was 37.8 years, and 77.5 % (69/89) of participants were female. We found that circulating asprosin concentrations were elevated in patients with overt and subclinical hypothyroidism compared to controls. Asprosin concentrations were positively correlated with TSH, Anti TPO, Anti TG, glucose, insulin, HOMA-IR and negatively correlated with FT4 and FT3. Conclusions: For the first time in the literature, this study has shown that asprosin concentration is increased in patients with hypothyroidism, and that increased asprosin concentrations are associated with increased serum glucose concentration and HOMA-IR index. Therefore, asprosin may be a useful new marker for early metabolic disorders in hypothyroid patients.
- 27 December 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (3) , 587-592
The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients
Purpose: The effect of subclinical thyroid pathologies on erythropoietin (EPO) treatment has not been well defined. The aim of the study is to compare the frequency and dose of EPO administration in patients with subclinical thyroid pathology and euthyroid hemodialysis patients. Methods: A cross-sectional and retrospective study was conducted with 210 patients. Special conditions were excluded, a total of 191 patients were included. Patients were divided into three groups. Results: The incidences of subclinical hypothyroidism, subclinical hyperthyroidism and euthyroidism were 10.5%, 3.1%, and 86.4%, respectively. Statistically significant difference was found between subclinical hypothyroid and euthyroid patients in terms of the number of patients using EPO (p = 0.0207), monthly total EPO doses (p = 0.003), and total monthly EPO doses per weight (p = 0.001). Conclusion The EPO dose required to achieve similar hemoglobin levels in hemodialysis patients was significantly higher in subclinical hypothyroid patients than in euthyroid patients.
- 27 December 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (3) , 587-592
The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients
Purpose: The effect of subclinical thyroid pathologies on erythropoietin (EPO) treatment has not been well defined. The aim of the study is to compare the frequency and dose of EPO administration in patients with subclinical thyroid pathology and euthyroid hemodialysis patients. Methods: A cross-sectional and retrospective study was conducted with 210 patients. Special conditions were excluded, a total of 191 patients were included. Patients were divided into three groups. Results: The incidences of subclinical hypothyroidism, subclinical hyperthyroidism and euthyroidism were 10.5%, 3.1%, and 86.4%, respectively. Statistically significant difference was found between subclinical hypothyroid and euthyroid patients in terms of the number of patients using EPO (p = 0.0207), monthly total EPO doses (p = 0.003), and total monthly EPO doses per weight (p = 0.001). Conclusion The EPO dose required to achieve similar hemoglobin levels in hemodialysis patients was significantly higher in subclinical hypothyroid patients than in euthyroid patients.
- 22 January 2022
- Published by Springer Nature in Neuroradiology
- Vol. 64 (7) , 1411-1418
Does concomitant prolactin measurement ıncrease the accuracy of ınferior petrosal sinus sampling?
Introduction Prolactin (PRL) measurement during inferior petrosal sinus sampling (IPSS) can be helpful to improve the accuracy. We aimed to evaluate the effect of measuring PRL levels as a predictor for the accuracy of IPSS and evaluate its impact on the lateralization of adenomas. Methods In this retrospective cohort study, we reviewed 51 patients who had undergone IPSS for the investigation of ACTH-dependent hypercortisolism. Results Forty-nine patients had proven Cushing’s disease (CD), one had EAS, and the remaining one patient had adrenal adenoma. Forty-seven patients had an above 2 ACTH IPS/P ratio at baseline, and all the post-corticotropin-releasing hormone (CRH) ACTH IPS/P ratios of patients with proven CD were above 3. In these two patients whose ACTH IPS/P ratio at baseline was below 2, PRL IPS/P ratios were above 1.8 in only the dominant side, which was considered secondary to a prolactin intersinus gradient due to the biological effects of the tumor. PRL-adjusted ACTH IPS/P ratios were > 1.3 in all patients with proven CD; it was 0.7 in the patient with EAS. Surgically confirmed positive lateralization was observed in 55.1% of patients with the ACTH gradient, but when PRL-adjusted ACTH IPS/IPS ratios were used in addition to the ACTH gradient, the ratio increased to 67.3%. Conclusion Although PRL-adjusted ACTH IPS/P ratios can be helpful to improve the accuracy of results during IPSS procedures, a prolactin intersinus gradient towards the ACTH-dominant side in patients with CD may invalidate PRL as an indicator of pituitary venous outflow.
- 22 January 2022
- Published by Springer Nature in Neuroradiology
- Vol. 64 (7) , 1411-1418
Does concomitant prolactin measurement ıncrease the accuracy of ınferior petrosal sinus sampling?
Introduction Prolactin (PRL) measurement during inferior petrosal sinus sampling (IPSS) can be helpful to improve the accuracy. We aimed to evaluate the effect of measuring PRL levels as a predictor for the accuracy of IPSS and evaluate its impact on the lateralization of adenomas. Methods In this retrospective cohort study, we reviewed 51 patients who had undergone IPSS for the investigation of ACTH-dependent hypercortisolism. Results Forty-nine patients had proven Cushing’s disease (CD), one had EAS, and the remaining one patient had adrenal adenoma. Forty-seven patients had an above 2 ACTH IPS/P ratio at baseline, and all the post-corticotropin-releasing hormone (CRH) ACTH IPS/P ratios of patients with proven CD were above 3. In these two patients whose ACTH IPS/P ratio at baseline was below 2, PRL IPS/P ratios were above 1.8 in only the dominant side, which was considered secondary to a prolactin intersinus gradient due to the biological effects of the tumor. PRL-adjusted ACTH IPS/P ratios were > 1.3 in all patients with proven CD; it was 0.7 in the patient with EAS. Surgically confirmed positive lateralization was observed in 55.1% of patients with the ACTH gradient, but when PRL-adjusted ACTH IPS/IPS ratios were used in addition to the ACTH gradient, the ratio increased to 67.3%. Conclusion Although PRL-adjusted ACTH IPS/P ratios can be helpful to improve the accuracy of results during IPSS procedures, a prolactin intersinus gradient towards the ACTH-dominant side in patients with CD may invalidate PRL as an indicator of pituitary venous outflow.